On April 24, the 3rd meeting of the 6th Board of Directors of DC PHARMA approved the " Proposal on Introducing Investors to the holding subsidiary for Capital Increase and Share Expansion ". It was agreed that Yantai Lannacheng Biotechnology Co., Ltd., as the holding subsidiary of DC PHARMA, would introduce investors in the way of capital increase and share expansion. Shenzhen Capital Group Co.,Ltd led the investment, and followed by Qianyanfangzhou, Yantai Caijing, Longxin Tongzi, Aohua Qingjie Nengyuan. This B+ financing successfully raised a total of RMB 300 million with a pre-investment valuation of RMB 1.95 billion.

After the completion of the capital increase and share expansion, LNC's registered capital was revised to 84.581897 million RMB. In accordance with LNC's development plan, a well-timed IPO financing listing will be implemented.

The investors of this capital increase and share expansion contributed to subscribe to LNC's registered capital, company's capital reserve, and the shareholding ratio is as follows:

The introduction of investors through LNC's capital increase and share expansion this time is advantageous for optimizing LNC's equity structure, enhancing its capital reserves, leveraging commercial investor resources, expediting the company's R&D process, striving for early product listing, bolstering its overall competitiveness, and fostering long-term development.

—— About LNC ——

Yantai Lannacheng Biotechnology Co., Ltd. (hereinafter referred to as LNC), headquartered in the beautiful beach city Yantai was jointly founded in 2021 by Yantai Dongcheng Pharmaceutical Group Co., Ltd. (hereinafter referred to as DC Pharma), one of China's leading nuclear medicine enterprises, and Professor Xiaoyuan (Shawn) Chen, a world expert in molecular imaging and nanomedicine.

Since its establishment, LNC has built a relatively complete radionuclide diagnosis and treatment (radiotheranostics) pipeline, covering small molecule, peptides, and antibodies based radioligands. LNC’s products address unmet clinical needs to diagnosing and treating multiple types of solid tumors, such as prostate cancer, gastric cancer, glioma, neuroendocrine tumors, lung cancer, thyroid cancer, and so on. Among them, fibroblast activation protein (FAP) and prostate specific membrane antigen (PSMA) related products have received IND approvals from US FDA, Singapore HSA and China NMPA and are in advanced stages of development global leading position.